Alzheimer’s drugs, which have been highly anticipated for their potential to combat cognitive decline, are now under intense scrutiny following a comprehensive review by Cochrane. This respected medical evidence evaluation institution has suggested that biological drugs targeting amyloid proteins do not provide substantial clinical benefits, despite their high costs and potential severe adverse effects. In light of these findings, the Czech-based H2 Global Group has proposed a novel alternative treatment involving molecular hydrogen to the governments of all 27 EU member states.
The Cochrane review, published on April 16, 2026, analyzed data from 17 clinical trials encompassing over 20,000 participants. It focused on anti-amyloid monoclonal antibodies used in patients with mild cognitive impairment and mild dementia caused by Alzheimer’s disease. The results indicated that the effects of these drugs were only “trivial,” lacking significant clinical impact, and highlighted a higher incidence of brain swelling and microhemorrhages (ARIA). Francesco Nonino, the lead author from the IRCCS Institute of Neurological Sciences in Bologna, emphasized the need for future Alzheimer’s research to explore different mechanisms of action beyond the amyloid pathway.
Reaction from global media and experts has been strong, with The Guardian describing the drug’s impact as “trivial” and The New York Times reporting on the debate over their clinical value. The BBC suggested that patients are unlikely to benefit, while Scientific American noted the absence of a meaningful clinical difference. European nations are also grappling with the high annual treatment costs, which are approximately €77,000 ($82,000 USD) per patient, complicating reimbursement processes.
In response to the Cochrane findings, H2 Global Group has put forward a strategic proposal to EU leaders, focusing on a combination of molecular hydrogen therapy and virtual reality (VR) cognitive rehabilitation. This approach, developed with a VR company’s certified medical device, is already implemented in over 40 European hospitals. Milan Krajíček, Chief Medical Officer at H2 Global Group, highlighted the importance of addressing oxidative stress and neuroinflammation to tackle Alzheimer’s. The firm’s strategy is based on a patent that protects the use of gaseous hydrogen for Alzheimer’s-type dementia, with plans for global expansion including the US.
The Czech Republic, led by H2 Global Group, sees a unique opportunity to lead a systemic solution to the aging population and dementia challenges. David Maršálek, CEO and Founder of H2 Global Group, emphasizes the potential for a large-scale clinical study to emerge from the Czech Republic, offering a safe and accessible solution for millions of patients. He calls for immediate action to bridge Czech innovation with pan-European collaboration, leveraging their Japanese-Czech technology and scientific backing to address this pressing health issue.